New Hope for Heart Damage Recovery After Heart Attack
Heart failure, which affects 64 million people globally, often develops after a heart attack. The sudden loss of blood flow causes irreversible damage to heart tissue, leading to the death of cardiac cells and diminished heart function. However, a groundbreaking study from the Weizmann Institute of Science in Israel reveals that Copaxone, a drug traditionally used to treat multiple sclerosis (MS), may protect the heart and support recovery after a heart attack.
Heart failure, which affects 64 million people globally, often develops after a heart attack. The sudden loss of blood flow causes irreversible damage to heart tissue, leading to the death of cardiac cells and diminished heart function. However, a groundbreaking study from the Weizmann Institute of Science in Israel reveals that Copaxone, a drug traditionally used to treat multiple sclerosis (MS), may protect the heart and support recovery after a heart attack.
How Does the Drug Work?
Copaxone was initially developed in the 1960s as a drug to mimic MS conditions for research purposes. Known for its immune-modulating properties, Copaxone helps optimize the immune response after a heart attack to promote healing.
Animal studies using mice have shown promising results. Regular use of Copaxone led to improved cardiac function, reduced scar tissue formation, and accelerated blood vessel regeneration.
Under the leadership of Professor Eldad Tzahor, the research team found that Copaxone does not force cardiac muscle cells to divide, but rather supports their survival. This reduces scarring in the left ventricle, enhancing the heart's ability to pump blood more effectively.
Human Trials and Future Prospects
This novel application of Copaxone highlights the potential of repurposing existing drugs for new medical challenges, offering faster pathways to clinical use. Human trials have already commenced at Hadassah Medical Center, where researchers expect to observe reduced immune responses and rapid improvement in heart function.
Despite its promise, Copaxone faces challenges due to its expired patent, which limits pharmaceutical companies' financial incentives to invest in this new application. Researchers hope that clinical success will draw support from healthcare organizations and government funding.
This discovery provides hope for millions of heart failure patients and could pave the way for innovative treatment strategies that repurpose established drugs, addressing unmet medical needs in a cost-effective and timely manner.